PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced that it has been granted a patent
PETALUMA, Calif., December 26, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has contracted with MEDsan, Inc.
PETALUMA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) — RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Anatoly Dritschilo, M.D. has joined
PETALUMA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) — RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Dessislava (Dessy) Boneva, M.D. has
PETALUMA, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Stephen Tannenbaum to the
PETALUMA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has submitted two provisional patent
PETALUMA, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has contracted with Avania CRO
PETALUMA, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced the launch of an Institutional Review Board
PETALUMA, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) — RetinalGeniX Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) released to the public via OTC Markets, a video webinar regarding the retinal
PETALUMA, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Fred Chasalow, Ph.D., to
